Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects

Clinical Pharmacology and Therapeutics

Volumn 69, Issue 5, 2001, Pages 317-323

  Stein, C Michael ^a   Sadeque, Abu J ^a   Murray, John J ^a   Wandel, Christoph ^a   Kim, Richard B ^a   Wood, Alastair J J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; PHYTOHEMAGGLUTININ;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; DRUG DISPOSITION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; ENVIRONMENTAL FACTOR; ETHNIC GROUP; GENETIC VARIABILITY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE;

ADMINISTRATION, ORAL; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AREA UNDER CURVE; CYCLOSPORINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; MALE;

EID: 0035338397     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.115073     Document Type: Article

References (33)

1. Kasiske BL, Neylan JF, Riggio RR, Danovitch GM, Kahana L, Alexander SR, et al. The effect of race on access and outcome in transplantation. New Engl J Med 1991;324:302-7.
2. Douzdjian V, Thacker LR, Blanton JW. Effect of race on outcome following kidney and kidney-pancreas transplantation in type I diabetics: The south-eastern organ procurement foundation experience. Clin Transplant 1997;11:470-5.
3. Tesi RJ, Deboisblanc M, Saul C, Frentz G, Etheredge E. An increased incidence of rejection episodes: One of the causes of worse kidney transplantation survival in black recipients. Arch Surg 1997;132:35-9.
4. Tejani A, Cortes L, Stablein D. Clinical correlates of chronic rejection in pediatric renal transplantation: A report of the North American pediatric renal transplant cooperative study. Transplantation 1996;61:1054-8.
5. Lindholm A, Welsh M, Alton C, Kahan BD. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability. Clin Pharmacol Ther 1992;52:359-71.
6. Schroeder TJ, Shah M, Hariharan S, First MR. Increased resources are required in patients with low cyclosporine bioavailability. Transplantat Proc 1996;28:2151-5.
7. Young CJ, Gaston RS. Renal transplantation in black Americans. New Eng J Med 2000;343:1545-52.
8. Neylan JF, for the US Renal Transplant Mycophenolate Mofetil Study Group. Immunosuppressive therapy in high-risk transplant patients: Dose dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 1997;64:1277-82.
9. Gaston RS, Hudson SL, Deierhoi MH, Barber WH, Laskow DA, Julian BA, et al. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression. Transplantation 1992;53:103-9.
10. Wood AJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991;20: 350-73.
11. Kovarik JM, Mueller EA, van BJ, Fluckiger SS, Lange H, Schmidt, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: A multicenter investigation in kidney transplant patients. Transplantation 1994;58:658-63.
12. Andrews PA, Sen M, Chang RW. Racial variation in dosage requirements of tacrolimus. Lancet 1996;348: 1446.
13. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
14. Sowunmi A, Rashid TJ, Akinyinka OO, Renwick AG. Ethnic differences in nifedipine kinetics: Comparisons between Nigerians, Caucasians and South Asians. Br J Clin Pharmacol 1995;40:489-93.
15. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther 2000;68:82-91.
16. Stein CM, Murray JJ, Wood AJJ. Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect. Clin Chem 1999;45:1477-84.
17. Murray JJ, Mullins MD, Knapp HR, Keeler SL, Serafin WE, Roberts LJ, et al. Regulation of the immune response by eicosanoids: Pharmacology and clinical effects of prostaglandin E in aspirin-sensitive syndromes. Am J Therapeutics 1995;2:739-48.
18. Butkus DE, Meydrech EF, Raju SS. Racial differences in the survival of cadaveric renal allografts: Overriding effects of HLA matching and socioeconomic factors. New Engl J Med 1992;327:840-5.
19. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667-71.
20. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90:1225-9.
21. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther 1999;66:288-94.
22. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000;67:48-56.
23. Kuehl P, Zhang J, Linn Y, Schuetz J, Watkins P, Daly A, et al. Sequence diversity in CYP3A promoters and an Sp1 site alteration that causes polymorphic CYP3A5 expression. Nat Genet. In press 2001.
24. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-8.
25. CAmpana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin: An update. Clin Pharmacokinet 1996;30:141-79.
26. DArbar D, Dell'Orto S, Morike K, Wilkinson GR, Roden DM. Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther 1997;61:292-300.
27. Pollak R, Wong RL, Chang CT. Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Neoral Study Group. Therapeutic Drug Monit 1999;21:661-3.
28. Min DI, Lee M, Ku YM, Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther 2000;68:478-86.
29. Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet 1996;30:107-40.
30. Kerman RH, Kimball PM, Lindholm A, Van BC, Katz SM, Lewis RM, et al. Immune risk factors: Impact on the incidence and diagnosis of rejection. Transplant Proc 1993;25:23-5.
31. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996;80:S40-5.
32. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992;357:692-4.
33. Awni WM. Pharmacodynamic monitoring of cyclosporin. Clin Pharmacokinet 1992;23:428-48.